lung
transplant
surviv
remain
significantli
impact
infect
develop
chronic
reject
manifest
bronchiol
obliteran
syndrom
bo
tradit
microbiolog
data
provid
insight
role
infect
bo
new
nonculturebas
techniqu
develop
character
entir
popul
microb
resid
surfac
bodi
also
known
human
microbiom
earli
studi
identifi
lung
transplant
patient
differ
lung
microbiom
demonstr
import
find
transplant
lung
microbiom
chang
time
furthermor
uniqu
bacteri
popul
longitudin
chang
lung
microbiom
suggest
play
role
develop
bo
futur
technolog
need
combin
function
assay
assess
immun
respons
lung
help
explain
microbiom
role
fail
lung
allograft
lung
transplant
increasingli
common
procedur
treat
intract
endstag
lung
diseas
appropri
patient
lung
transplant
perform
repres
largest
number
given
year
transplant
chronic
obstruct
pulmonari
diseas
copd
interstiti
lung
diseas
includ
idiopath
pulmonari
fibrosi
ipf
cystic
fibrosi
cf
account
nearli
procedur
despit
growth
lung
transplant
remain
limit
high
mortal
rate
rel
solid
organ
transplant
median
report
surviv
year
thirtieth
offici
lung
heartlung
transplant
report
registri
intern
societi
heart
lung
transplant
releas
major
mortal
within
first
year
transplant
due
infect
contrast
late
mortal
lung
transplant
larg
due
chronic
reject
manifest
bronchiol
obliteran
syndrom
bo
improv
surviv
lung
transplant
time
larg
due
improv
earli
mortal
without
signific
chang
develop
bo
time
mind
breakthrough
need
prevent
bo
provid
meaning
substanti
impact
longterm
surviv
lung
transplant
role
microbi
infect
develop
bo
long
suspect
evalu
tradit
microbiolog
studi
recent
noncultur
base
techniqu
develop
util
highthroughput
dna
sequenc
broadli
character
microbiom
commun
bacteria
occupi
surfac
human
bodi
techniqu
entir
popul
bacteria
character
tradit
cultur
may
appear
steril
role
commens
organ
dysbiosi
bacteri
colon
diseas
state
bo
better
establish
research
microbiom
lung
diseas
earli
stage
begun
appli
lung
transplant
potenti
impact
microbiota
allograft
compel
microbiom
consist
entir
commun
microorgan
product
resid
within
human
bodi
evalu
microbiom
becom
possibl
due
prolifer
increasingli
inexpens
highthroughput
dna
sequenc
technolog
bacteria
contain
highli
conserv
rrna
gene
known
amplifi
sequenc
use
identifi
resid
bacteria
comparison
databas
known
sequenc
addit
function
metagenom
analysi
may
perform
identifi
biolog
task
may
perform
microbi
commun
figur
amplif
rna
gene
har
much
bacteri
microbiom
work
date
allow
bacteri
sequenc
select
sampl
also
contain
eukaryot
dna
techniqu
avail
evalu
fungom
virom
techniqu
less
develop
littl
publish
regard
lung
diseas
consequ
focu
research
bacteri
microbiom
lung
howev
sinc
bronchoscopi
requir
travers
oral
caviti
import
concern
aris
regard
distinct
carryov
upper
respiratori
tract
occur
procedur
clinic
signific
lower
airway
microbiota
may
present
due
continu
natur
aerodigest
tract
differ
sampl
techniqu
well
novel
statist
analysi
use
address
challeng
furthermor
lung
microbiom
may
uniform
suggest
studi
copd
demonstr
region
heterogen
microbi
popul
major
publish
studi
util
bronchoalveolar
lavag
bal
may
reflect
segment
variat
airway
microbiom
addit
low
biomass
microorgan
result
low
yield
bacteria
sequenc
therefor
increas
import
interfer
background
environment
bacteria
detect
sampl
equip
reagent
final
sequenc
obtain
may
reflect
dead
bacteria
thu
import
question
remain
unansw
gold
standard
method
determin
lung
microbiom
human
subject
sampl
lung
allograftth
natur
transplant
also
provid
substanti
benefit
studi
microbiom
popul
part
due
increas
sampl
post
transplant
allograft
routin
schedul
surveil
clinic
indic
bronchoscopi
result
allow
transplant
popul
first
longitudin
bronchoscop
microbiom
studi
frequent
healthcar
followup
allow
detail
track
phenotyp
infecti
complic
howev
sever
addit
challeng
interpret
post
lung
allograft
microbiom
includ
nativ
lung
microbiom
recipi
residu
microbiom
hostdonor
interact
effect
allograft
microbiom
complic
effect
immunosuppress
drug
microbi
popul
lung
allograft
unknown
lung
allograft
microbiom
come
microbiota
present
lung
allograft
mani
potenti
sourc
includ
environment
acquisit
cours
normal
respir
carryov
upper
respiratori
tract
recipi
carryov
remain
nativ
lung
singl
lung
transplant
retain
microbiota
donor
lung
spillov
aerodigest
tract
donor
lung
exampl
presenc
burkholderia
cenocepacia
pretranspl
consist
link
excess
mortal
transplant
presenc
exclud
patient
transplant
center
microbiom
studi
begun
address
question
dickson
et
al
report
effect
pretranspl
diagnosi
lung
allograft
microbi
popul
willner
colleagu
demonstr
lung
microbiom
lung
transplant
recipi
cf
distinct
pretranspl
diagnos
extent
differ
repres
carryov
exist
microbiota
underli
immun
profil
diseas
remain
unclear
donor
lung
nativ
lung
microbiotahealthi
lung
detect
nativ
microbiom
although
degre
repres
spillov
upper
respiratori
tract
uniqu
taxa
remain
analyt
challeng
healthi
donor
lung
carri
nativ
microbiom
recipi
date
publish
studi
evalu
donor
lung
pretranspl
result
impact
donor
microbiota
interact
donor
recipi
microbiota
unclear
similarli
effect
remain
nativ
lung
recipi
singl
lung
transplant
also
unclear
futur
research
must
direct
determin
nativ
donor
lung
microbiota
longitudin
chang
interact
spillov
aerodigest
tractgastroesophag
reflux
gerd
associ
sever
differ
lung
diseas
includ
ipf
addit
recent
data
suggest
gerd
associ
wors
outcom
lung
transplant
gerd
aspir
could
lead
steril
inflamm
clearli
deposit
digest
tract
may
caus
shift
airway
microbiom
seed
nasal
oral
caviti
discuss
detail
role
upper
airway
microbiom
addit
sourc
microbiota
character
interact
lung
allograft
microbiom
need
bacteri
communitiesmicrobiom
studi
lung
transplant
recipi
begun
fundament
demonstr
bacteri
microbiom
lung
transplant
recipi
appear
differ
healthi
control
patient
charlson
et
al
evalu
oral
lung
microbiom
lung
transplant
recipi
compar
healthi
control
transplant
patient
overal
higher
bacteri
load
bronchoalveolar
lavag
fluid
balf
balf
healthi
patient
microbi
content
mirror
oral
flora
subset
lung
transplant
recipi
three
cf
one
ipf
balf
domin
organ
name
pseudomona
staphylococcu
achromobact
also
demonstr
tradit
cultur
contrast
one
subject
late
bo
balf
domin
sneathia
unabl
cultur
result
suggest
noncultur
techniqu
may
complement
tradit
cultur
detect
certain
bacteri
speci
addit
studi
confirm
lung
transplant
microbiom
appear
distinct
borecwicz
et
al
small
sampl
lung
transplant
recipi
control
confirm
signific
differ
bacteri
popul
transplant
healthi
lung
furthermor
luna
et
al
found
transplant
cf
patient
differ
microbi
popul
nontranspl
cf
patient
nontranspl
cf
patient
demonstr
predomin
firmicut
phylum
transplant
cf
patient
greatest
abund
phylum
proteobacteria
predomin
genu
acinetobact
separ
analysi
lung
transplant
recipi
dickson
et
al
found
signific
differ
lung
transplant
recipi
control
phylum
proteobacteria
favor
bacteroidet
firmicut
lastli
roger
et
al
found
transplant
patient
like
pseudomona
staphylococcu
proprionobacterium
veillonella
addit
studi
consist
shown
microbiota
transplant
lung
distinct
nontranspl
lung
measur
bacteri
commun
divers
word
taxonom
distribut
within
commun
vari
lung
transplant
recipi
roger
et
al
found
transplant
patient
differ
bacteria
similar
divers
balf
compar
control
patient
contrast
dickson
et
al
note
decreas
divers
balf
lung
transplant
recipi
compar
control
analysi
loss
divers
mostli
occur
lung
transplant
recipi
symptomtrigg
bronchoscopi
associ
clinic
infect
oppos
routin
surveil
bronchoscopi
charlson
colleagu
found
rich
divers
lower
transplant
patient
strongest
effect
transplant
suppur
lung
diseas
result
suggest
loss
divers
may
tie
emerg
predomin
organ
period
infect
fungal
populationsther
one
publish
studi
evalu
fungal
popul
oral
wash
balf
lung
transplant
recipi
studi
charlson
colleagu
show
fungal
popul
oral
wash
predominantli
environment
fungi
candida
speci
fungal
popul
balf
distinct
transplant
popul
compar
healthi
control
transplant
patient
demonstr
candida
aspergillu
cryptococcu
speci
notabl
often
discord
oral
sampl
initi
studi
demonstr
potenti
studi
fungal
popul
allograft
longitudin
analysisth
posttranspl
period
uniqu
surveil
bronchoscopi
routin
perform
allow
repeat
sampl
lung
microbiota
reason
lung
transplant
first
area
lung
microbiom
research
produc
longitudin
invas
evalu
individu
lung
microbiom
longitudin
evalu
four
transplant
patient
borewicz
et
al
found
substanti
variat
microbi
popul
transplant
recipi
fewer
popul
retain
time
luna
et
al
also
demonstr
tempor
chang
bacteri
divers
divers
increas
month
decreas
month
willner
et
al
undertook
holist
sampl
multipl
bodi
site
lung
transplant
recipi
use
balf
lung
tissu
nasopharyng
oral
rectal
swab
balf
sampl
strongli
affect
antibiot
pressur
gradual
signific
decreas
shannon
divers
index
willner
colleagu
separ
show
lung
transplant
recipi
cf
six
bo
demonstr
dynam
microbiota
time
antibiot
pressur
play
import
role
dynam
microbiom
impact
presenc
pseudomona
notabl
investig
larg
found
microbiom
allograft
dynam
antibiot
one
import
factor
influenc
yet
identifi
bo
physiolog
correl
oblit
bronchiol
defin
progress
develop
airflow
obstruct
without
altern
explan
infect
acut
reject
approxim
lung
transplant
recipi
develop
bo
within
year
transplant
ten
year
figur
bo
mortal
high
account
major
death
year
posttranspl
tabl
propos
mechan
bo
includ
activ
innat
immun
system
immun
activ
allograft
humor
autoimmun
respons
extern
factor
aspir
infect
figur
role
infect
develop
bo
studi
tradit
method
studi
noncultur
base
method
infect
common
caus
death
earli
lung
transplant
cours
also
compel
link
certain
infect
subsequ
develop
bo
studi
perform
tradit
microbiolog
serum
antibodi
detect
techniqu
recent
nonculturebas
microbiom
analyt
techniqu
focus
role
bacteria
sever
studi
lung
transplant
recipi
suggest
lung
microbiom
distinct
patient
develop
bo
dickson
et
al
found
microbiom
significantli
differ
without
bo
time
bronchoscopi
willner
et
al
also
note
lung
transplant
recipi
cf
develop
bo
coinfect
recogn
cf
pathogen
stenotrophomona
achromobact
haemophilu
develop
bo
addit
chang
lung
microbiom
time
may
associ
bo
poroyko
colleagu
found
patient
eventu
develop
bo
predomin
firmicut
nonbo
patient
predomin
proteobacteria
patient
bo
also
demonstr
increas
variabl
microbiom
time
compar
patient
without
bo
chang
microbi
commun
divers
relat
bo
differ
studi
willner
et
al
found
bo
associ
signific
decreas
shannon
index
divers
contrast
dickson
et
al
find
associ
differ
find
microbi
commun
divers
may
depend
sever
clinic
factor
yet
defin
pseudomonasmicrobiom
analysi
tradit
cultur
studi
overlap
investig
role
pseudomona
posttranspl
presenc
pseudomona
aeruginosa
colon
unlik
gram
neg
bacteria
associ
develop
bo
strong
bodi
literatur
util
tradit
cultur
retrospect
singlecent
studi
vo
et
al
evalu
lung
transplant
recipi
found
postop
colon
pseudomona
risk
factor
bo
associ
wors
bo
stage
surviv
univari
analysi
multivari
analysi
trend
toward
colon
risk
bo
still
seen
studi
look
impact
pretranspl
posttranspl
pseudomona
airway
colon
fate
colon
time
pseudomona
establish
airway
posttranspl
shown
play
role
bo
develop
prospect
studi
adult
cf
patient
demonstr
patient
whose
transplant
lung
remain
free
pseudomona
less
like
develop
bo
separ
studi
recipi
without
cf
botha
et
al
evalu
patient
new
develop
persist
preoper
colon
p
aeruginosa
transplant
patient
becam
cultur
posit
p
aeruginosa
interestingli
patient
de
novo
colon
higher
likelihood
develop
bo
compar
either
never
colon
colon
pretranspl
pseudomona
statist
analysi
emphas
impact
time
pseudomona
infect
outcom
lung
transplant
gregson
et
al
suggest
interact
presenc
pseudomona
immun
system
lead
bo
may
depend
patient
state
time
pseudomona
establish
allograft
use
cox
semimarkovian
approach
likelihood
transit
three
state
lung
transplant
bo
death
assess
model
pseudomona
clinic
infect
increas
risk
develop
new
bo
death
prior
develop
bo
patient
elev
bal
fluid
chemokin
pseudomona
infect
risk
amplifi
addit
diagnosi
bo
establish
pseudomona
infect
colon
led
increas
risk
death
similarli
use
microbiom
analysi
willner
colleagu
also
demonstr
link
reestablish
pseudomona
present
pretranspl
lung
cf
recipi
decreas
risk
bo
studi
evalu
bal
microbiom
transplant
patient
bo
cystic
fibrosi
underli
transplant
etiolog
patient
cf
bo
nontyp
pathogen
includ
streptococcu
lactobacillu
enterococcu
neisseria
haemophilu
cf
patient
without
bo
like
demonstr
pseudomona
burkholderia
staphylococcu
noncf
popul
patient
bo
demonstr
shift
popul
normal
respiratori
flora
new
pathogen
includ
pseudomona
burkholderia
staphylococcu
result
impli
relationship
preand
posttranspl
microbiota
may
impact
develop
bo
sum
data
suggest
research
combin
tradit
cultur
method
well
noncultur
techniqu
identifi
global
lung
microbi
popul
well
individu
bacteria
may
contribut
health
well
lung
diseas
tradit
cultur
studi
pseudomona
colon
prompt
first
attempt
modif
specif
bacteri
organ
influenc
bo
develop
given
upper
airway
like
reservoir
pseudomona
cystic
fibrosi
vital
et
al
perform
endoscop
frontalsphenoethoidectomi
major
patient
cf
underw
lung
transplant
goal
treat
bacteri
colon
sinus
immedi
post
transplant
patient
pseudomona
airway
colon
pretranspl
patient
pulmonari
colon
nasal
colon
persist
colon
transplant
despit
trial
erad
multipl
antibiot
activ
pseudomona
compar
patient
persist
pseudomona
airway
colon
patient
without
pseudomona
improv
surviv
decreas
incid
bo
patient
pseudomona
also
like
neutrophil
alveol
indic
presenc
pseudomona
lead
airway
inflamm
immun
activ
studi
window
potenti
therapeut
use
microbiom
studi
demonstr
difficulti
erad
bacteri
inhabit
import
pretranspl
microbiota
posttranspl
allograft
azithromycinazithromycin
macrolid
antibiot
shown
protect
bo
death
notabl
retrospect
analysi
lung
transplant
recipi
bo
demonstr
patient
receiv
azithromycin
surviv
advantag
particularli
treatment
initi
bo
stage
mechan
azithromycin
set
uncertain
may
due
immunomodulatori
role
altern
explan
antibiot
properti
azithromycin
may
alter
lung
microbiota
benefici
way
systemat
evalu
azithromycin
allograft
microbiom
done
one
instanc
moraxella
decreas
treatment
azithromycin
clearli
area
deep
interest
futur
research
bacteri
microbiom
data
becom
robust
yet
publish
literatur
regard
role
microorgan
commun
relat
bo
howev
tradit
literatur
provid
evid
virus
fungi
import
virusesth
role
communityacquir
respiratori
virus
reliabl
shown
associ
develop
bo
retrospect
cohort
studi
consecut
adult
lung
transplant
patient
communityacquir
upper
lower
respiratori
viral
ill
identifi
includ
respiratori
syncyti
viru
rsv
parainfluenza
influenza
adenoviru
group
viral
infect
like
develop
bo
death
deathfrombo
lower
respiratori
tract
infect
enhanc
risk
subsequ
prospect
singlecent
studi
lung
transplant
recipi
variou
time
posttranspl
screen
nasopharyng
oropharyng
swab
differ
communityacquir
respiratori
virus
thirtyfour
virus
detect
patient
includ
parainfluenza
rsv
metapneumoviru
coronaviru
rhinoviru
influenza
patient
viru
detect
oneyear
incid
new
bo
compar
virusneg
patient
influenza
pneumonia
also
associ
progress
loss
lung
function
well
risk
graft
dysfunct
lung
transplant
recipi
similarli
prospect
evalu
kumar
et
al
show
transplant
recipi
respiratori
viru
document
patient
least
one
bal
acut
reject
declin
fev
occur
within
three
month
patient
document
respiratori
viru
compar
without
respiratori
viral
infect
chronic
reject
defin
oblit
bronchiol
histolog
clinic
bo
diagnos
patient
within
year
infect
rsv
infect
also
associ
onset
rapid
develop
bo
virus
implic
bo
ebv
thu
viral
infect
interact
microbi
commun
import
target
research
expand
realm
cmv
replic
allograft
treatment
cmv
pneumon
within
first
six
month
transplant
associ
increas
risk
bo
fiser
et
al
found
cmv
risk
factor
progress
bo
contrast
studi
literatur
found
cmv
detect
bronchoalveolar
lavag
histolog
diagnos
cmv
pneumonia
treat
ganciclovir
relationship
subsequ
develop
bo
surviv
likewis
presenc
betaherpesvirus
includ
cmv
human
herpesviru
hhv
associ
acut
reject
develop
bo
despit
conflict
result
prophylaxi
cmv
associ
decreas
risk
bo
surviv
thu
role
specif
viral
infect
remain
unclear
unknown
whether
presenc
baselin
microbi
commun
explain
varianc
studi
aspergillusdetect
aspergillu
associ
bo
tradit
cultur
aspergillu
colon
describ
posit
cultur
without
evid
invas
diseas
associ
bo
mortal
bo
studi
patient
singl
center
furthermor
gregson
et
al
found
aspergillu
isol
associ
increas
risk
develop
bo
increas
risk
death
bo
coinfectionth
interact
viral
fungal
ill
bacteri
infect
may
enhanc
risk
bo
multivari
analysi
patient
document
respiratori
viral
ill
coexist
bacteria
time
initi
viral
ill
associ
graft
dysfunct
year
viral
infect
use
nonculturebas
techniqu
willner
et
al
found
aspergillusposit
balf
cultur
never
occur
conjunct
pseudomonasdomin
commun
suggest
pseudomonasaspergillu
antagon
organ
associ
bo
implic
find
relationship
bo
clear
minimum
strike
exampl
import
look
whole
microbi
commun
viral
bacteri
fungal
futur
research
upper
airway
microbiom
connect
lung
microbiometh
upper
airway
microbiom
includ
resid
nasopharynx
oropharynx
like
import
reservoir
lung
microbiom
willner
et
al
also
note
transplant
patient
control
share
background
lung
microbiom
character
oral
upper
respiratori
tract
flora
includ
streptococcu
veillonella
prevotella
import
support
evid
come
topograph
sampl
respiratori
tract
healthi
patient
lung
diseas
includ
transplant
lung
charlson
colleagu
evalu
oral
microbiota
addit
balf
found
subject
balf
remain
close
link
oral
wash
patient
diverg
oral
wash
balf
strongest
transplant
patient
likewis
willner
et
al
also
determin
chang
balf
commun
mirror
chang
nasopharyng
commun
contrast
charlson
et
al
found
normal
lung
nasopharyng
commun
appear
distinct
lower
respiratori
tract
oral
microbiota
larg
unchang
patient
immedi
transplant
major
organ
expect
genera
streptococcu
veillonella
patient
develop
respiratori
sign
symptom
notabl
shift
oral
microbiota
popul
unclear
respiratori
infect
subsequ
antibiot
treatment
led
shift
oral
microbiom
microbiom
predispos
respiratori
symptom
likewis
oral
microbiom
pediatr
liver
transplant
patient
shown
initi
chang
day
revert
pretranspl
state
day
contrast
oral
microbiom
late
transplant
may
alter
diaz
et
al
found
oral
microbiom
differ
recipi
renal
cardiac
transplant
one
year
posttranspl
compar
nontranspl
control
transplant
patient
like
bacteria
phyla
gammaproteobacteria
klebsiella
pseudomona
acinetobact
vibrio
enterobacteriacea
presenc
organ
posit
correl
dose
prednison
mycophenol
mofetil
studi
suggest
oral
microbiota
dynam
entiti
may
chang
due
post
transplant
immunosuppress
antibiot
clinic
factor
associ
transplant
impact
oral
microbiota
lung
microbiota
still
unclear
stem
cell
transplantationearli
mous
studi
suggest
presenc
microbiota
increas
risk
gut
graftversushost
diseas
gvhd
stemcel
transplant
recipi
lead
practic
gut
decontamin
condit
transplant
direct
role
microbiota
unknown
murin
studi
shown
modul
innat
immun
pathway
lead
differ
gvhd
howev
studi
modern
era
microbiom
analysi
yet
publish
given
similar
bo
lung
transplant
gvhd
lung
stem
cell
transplant
data
may
provid
import
inform
regard
develop
bo
lung
transplant
small
bowel
liver
transplantationstudi
patient
small
bowel
liver
recipi
provid
import
clue
chang
natur
microbiota
set
transplant
recipi
small
bowel
transplant
found
shift
ileostomi
microbiota
directli
relat
increas
exposur
oxygen
environ
find
emphas
role
anatom
microenviron
may
also
occur
lung
transplant
diseas
lung
anim
human
studi
cirrhosi
demonstr
stool
dysbiosi
associ
underli
cirrhosi
normal
transplant
highlight
potenti
import
underli
diseas
state
microbiom
final
studi
liver
small
bowel
demonstr
potenti
clinic
correl
reject
associ
disrupt
microbiota
oh
et
al
found
bacteri
fingerprint
ileal
effluent
could
distinguish
reject
nonreject
recipi
small
bowel
transplant
murin
studi
liver
transplant
acut
reject
associ
alter
gut
microbiota
microbialassoci
molecul
pattern
may
lead
increas
suscept
liver
preserv
reperfus
injuri
transplant
whether
similar
pattern
could
becom
predict
tool
treatment
target
lung
transplant
remain
seen
research
lung
microbiom
nascent
stage
basic
question
sampl
techniqu
analysi
still
answer
lung
transplant
provid
uniqu
opportun
sequenti
sampl
lung
microbiom
transplant
pulmonologist
routin
perform
bronchoalveolar
lavag
transbronchi
biopsi
sever
time
point
transplant
mind
lung
transplant
tremend
promis
earli
area
advanc
understand
lung
allograft
microbiom
current
data
suggest
lung
transplant
microbiom
differ
healthi
lung
microbiom
addit
major
studi
suggest
lung
transplant
microbiom
decreas
divers
rich
suggest
differ
divers
importantli
longitudin
chang
bacteri
flora
describ
rais
question
whether
chang
microbiota
time
import
individu
pathogen
develop
bo
futur
microbiom
research
excit
transit
necessari
descript
studi
mechanist
understand
microbiom
transplant
next
five
year
expect
field
lung
transplant
microbiom
research
standard
sampl
collect
establish
relationship
donor
lung
microbiota
posttranspl
state
well
determin
effect
immunosuppress
antibiot
lung
microbiom
research
move
beyond
initi
stage
descript
studi
look
function
microbi
commun
within
lung
microbiom
studi
must
link
assess
innat
adapt
immun
function
within
lung
allograft
metabol
product
lung
microbi
commun
must
identifi
determin
role
diseas
develop
assess
microbiom
may
ultim
use
predictor
patient
risk
reject
bo
may
provid
therapeut
target
final
technolog
evolv
evalu
fungom
virom
must
also
includ
analysi
microorgan
lung
transplant
ad
anoth
dimens
alreadi
complex
system
bacteri
fungal
viral
commun
interact
new
noncultur
base
techniqu
use
dna
sequenc
identifi
entir
microbi
popul
surfac
bodi
techniqu
begin
appli
lung
transplant
recipi
infect
bronchiol
obliteran
syndrom
bo
major
caus
death
lung
transplant
recipi
studi
lung
allograft
microbiom
may
provid
new
understand
complic
target
therapi
microbiota
lung
transplant
recipi
differ
healthi
control
patient
howev
drive
forc
behind
differ
prognost
implic
differ
unclear
develop
bo
strongli
link
bacteria
viral
fungal
infect
tradit
microbiolog
studi
current
analys
lung
microbiom
suggest
import
differ
lung
transplant
recipi
without
bo
signific
differ
need
investig
major
futur
direct
includ
understand
interact
differ
microbi
popul
human
immun
system
har
microbiom
analysi
prognost
tool
therapeut
target
bioinformat
method
function
metagenom
otu
oper
taxonom
unit
cluster
organ
similar
sequenc
level
beyond
threshhold
eg
use
place
speci
genu
etc
